These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 7706986

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Use of somatostatin analogue scintigraphy in the localization of recurrent medullary thyroid carcinoma.
    Bernà L, Chico A, Matías-Guiu X, Mato E, Catafau A, Alonso C, Mora J, Mauricio D, Rodríguez-Espinosa J, Marí C, Flotats A, Martín JC, Estorch M, Carrió I.
    Eur J Nucl Med; 1998 Nov; 25(11):1482-8. PubMed ID: 9799343
    [Abstract] [Full Text] [Related]

  • 8. Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings.
    Adams S, Baum RP, Hertel A, Schumm-Draeger PM, Usadel KH, Hör G.
    Eur J Nucl Med; 1998 Sep; 25(9):1277-83. PubMed ID: 9724377
    [Abstract] [Full Text] [Related]

  • 9. Radiolabeled somatostatin analog scintigraphy in medullary thyroid carcinoma and carcinoid tumor.
    Rufini V, Salvatori M, Saletnich I, Valenza V, Maussier ML, Martino G, Corsello SM, Pantusa M, Casolo A, Troncone L.
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):140-4. PubMed ID: 9002774
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Preparation and clinical evaluation of technetium-99m dimercaptosuccinic acid for tumour scintigraphy.
    Hirano T, Tomiyoshi K, Zhang YJ, Ishida T, Inoue T, Endo K.
    Eur J Nucl Med; 1994 Jan; 21(1):82-5. PubMed ID: 8088289
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Combined use of 111In-DTPA-D-Phe-1-octreotide (OCT) and 123I-vasoactive intestinal peptide (VIP) in the localization diagnosis of medullary thyroid carcinoma (MTC).
    Kurtaran A, Leimer M, Kaserer K, Yang Q, Angelberger P, Niederle B, Virgolini I.
    Nucl Med Biol; 1996 May; 23(4):503-7. PubMed ID: 8832707
    [Abstract] [Full Text] [Related]

  • 16. The role of radiopharmaceuticals MIBG and (V) DMSA in the diagnosis of medullary thyroid carcinoma.
    Verga U, Muratori F, Di Sacco G, Banfi F, Libroia A.
    Henry Ford Hosp Med J; 1989 May; 37(3-4):175-7. PubMed ID: 2576958
    [Abstract] [Full Text] [Related]

  • 17. Technetium 99m pentavalent dimercaptosuccinic acid and thallium 201 in detecting recurrent medullary carcinoma of the thyroid.
    Bigsby RJ, Lepp EK, Litwin DE, Wilkinson AA, Matte GG.
    Can J Surg; 1992 Aug; 35(4):388-92. PubMed ID: 1323381
    [Abstract] [Full Text] [Related]

  • 18. Pentavalent Tc-99m DMSA accumulation in a medullary carcinoma of the thyroid.
    Hirano T, Otake H, Watanabe N, Oriuchi N, Fukuda T, Endo K.
    Clin Nucl Med; 1997 May; 22(5):339-40. PubMed ID: 9152545
    [No Abstract] [Full Text] [Related]

  • 19. Medullary carcinoma of the thyroid: management of persistent hypercalcitonaemia utilizing [99mTc] (v) dimercaptosuccinic acid scintigraphy.
    Udelsman R, Mojiminiyi OA, Soper ND, Buley ID, Shepstone BJ, Dudley NE.
    Br J Surg; 1989 Dec; 76(12):1278-81. PubMed ID: 2557953
    [Abstract] [Full Text] [Related]

  • 20. Comparative radionuclide imaging of metastatic insular carcinoma of the thyroid: value of technetium-99m-(V)DMSA.
    Yen TC, King KL, Yang AH, Liu RS, Yeh SH.
    J Nucl Med; 1996 Jan; 37(1):78-80. PubMed ID: 8544007
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.